相关实验视频
Updated: Jul 2, 2025

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
UPP1通过AKT增强了膀癌的进展和耐 gemcitabine 耐药性
Wenzhi Du1,2, Sheng Tu1,3, Wenxiu Zhang4
1Hubei Key Laboratory of Urological Diseases, Laboratory of Precision Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
尿素酸化酶1 (UPP1) 通过激活AKT通路来促进膀癌的生长,迁移和耐 gemcitabine 的抵抗. 抑制UPP1或AKT可能是膀癌的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 尿素酸化酶1 (UPP1) 参与了皮里米丁的代谢.
- 目前尚不清楚UPP1在膀癌 (BLCA) 中的作用.
- 在各种癌症中,AKT信号通路经常被激活,从而促进瘤发生.
研究的目的:
- 研究UPP1在膀癌中的作用.
- 阐明UPP1影响BLCA进展和凝胺耐药性的机制.
- 评估UPP1作为BLCA的潜在治疗点.
主要方法:
- 使用BLCA细胞系和动物模型进行体外和体外研究.
- 分析AKT信号通路的激活,包括酸化和蛋白质与蛋白质相互作用.
- 细胞增殖,迁移,入侵和对gemcitabine敏感性的评估.
- 药理上抑制UPP1和AKT,以及对UPP1.1进行基因操纵.
主要成果:
- UPP1显著促进BLCA细胞的增殖,迁移,入侵,以及对gemcitabine的抗性.
- UPP1通过促进AKT与PDK1/PDK2的结合和酸3,4,5-三酸盐的招募来激活AKT信号通路.
- 抑制UPP1或AKT会取消UPP1驱动的瘤进展和耐药性,而AKT激活会恢复这些效应.
结论:
- 在膀癌中,UPP1起到关键的瘤基因作用.
- UPP1通过激活AKT信号通路来增强瘤发生和凝胺耐药性.
- UPP1代表了膀癌治疗的有前途的治疗标.
更多相关视频
06:12Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
Published on: May 29, 2015
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
相关概念视频
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
PI3K/mTOR/AKT Signaling Pathway
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...